1. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Issue 12 (December 2016) Authors: Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A; Aisner, Seena C; Bowden, Michaela; Huang, Ying; Carbone, David P; Gerstner, Gregory J; Lerner, Rachel E; Rubin, Jerome L; Owonikoko, Taofeek K; Stella, Philip J; Steen, Preston D; Khalid, Ahmed Ali; Ramalingam, Suresh S Journal: Lancet oncology Issue: Volume 17:Issue 12(2016:Dec.) Page Start: 1661 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗